Aduro BioTech Finds $55M

Berkeley-based Aduro Biotech has raised $55M in a Series C funding, the company said this week, for the company's immunotherapy efforts targeting cancer. The company said the funding came from Johnson & Johnson Development Corporation (JJDC), along with Morningside Group and other investors. Aduro Biotech said it has now raised a total of $84M in equity funding. The company is led by Stephen T. Isaacs.